Request Demo

Last update 14 Apr 2025

Ciprofloxacin

Last update 14 Apr 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryCiprofloxacin is a fluoroquinolone antibiotic used to treat a number of bacterial infections. It can be taken by mouth, as eye drops, as ear drops, or intravenously. It is a second-generation fluoroquinolone with a broad spectrum of activity that usually results in the death of the bacteria. Ciprofloxacin was patented in 1980 and introduced in 1987. It is on the World Health Organization's List of Essential Medicines. The World Health Organization classifies ciprofloxacin as critically important for human medicine. It is available as a generic medication.Common side effects include nausea, vomiting, and diarrhea. Severe side effects include an increased risk of tendon rupture, hallucinations, and nerve damage.

Drug Type

Small molecule drug

Synonyms

Ciprfloxacin Lactate and Sodium Chloride, Ciprofioxacin Lactate, Ciprofloxacin (JP17/USP/INN)

+ [29]

Target

Bacterial DNA gyrase

Action

inhibitors

Mechanism

Bacterial DNA gyrase inhibitors(Bacterial DNA gyrase inhibitors)

Therapeutic Areas

Infectious DiseasesDigestive System DisordersOtorhinolaryngologic Diseases+ [4]

Active Indication

PlagueBronchiectasisBacterial prostatitis+ [24]

Inactive Indication

Acute otitis externaAcute otitis mediaBurns+ [11]

Originator Organization

Meiji Seika Pharma Co., Ltd.

Active Organization

Bayer HealthCare Pharmaceuticals, Inc.

Bayer Yakuhin Ltd.Ipca Pharma (Australia) Pty Ltd.

+ [2]

Inactive Organization

Bayer AG

Novartis Pharmaceuticals Corp.

Otonomy, Inc.

+ [4]

Drug Highest PhaseApproved

First Approval Date

Japan (01 Jan 1987),

Bacterial Infections

RegulationAccelerated Approval (United States), Orphan Drug (United States)

Structure/Sequence

Molecular FormulaC17H18FN3O3

InChIKeyMYSWGUAQZAJSOK-UHFFFAOYSA-N

CAS Registry85721-33-1

256

Clinical Trials associated with Ciprofloxacin

ChiCTR2500099448

/ SuspendedNot ApplicableIIT

Observation on the Anesthetic Effect of Low-dose Remazolam Combined with Ciprofloxacin for Painless Gastroscopy

Start Date01 Apr 2025

Sponsor / Collaborator-

NCT06810583

/ Not yet recruitingPhase 1IIT

A Prospective, Single-Arm, Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia

This is a single-arm pilot clinical trial evaluating dalbavancin-based prophylaxis in children and adolescents with acute myeloid leukemia or relapsed lymphoblastic leukemia receiving myelosuppressive chemotherapy.
Primary objective:
- To estimate the rate of bacterial bloodstream infection in pediatric patients with AML or relapsed ALL undergoing chemotherapy receiving dalbavancin-based prophylaxis
Secondary objectives:
* To describe the population pharmacokinetics of every 28 days dalbavancin up to 12 weeks in pediatric patients with AML or relapsed ALL undergoing chemotherapy
* To describe the tolerability of every 28 days dalbavancin prophylaxis in pediatric patients with AML or relapsed ALL undergoing chemotherapy
* To describe the acceptability of every 28 days dalbavancin prophylaxis in pediatric patients with AML or relapsed ALL undergoing chemotherapy
* To estimate the rates of likely bacterial infections, Clostridioides difficile infection, and febrile neutropenia in pediatric patients receiving dalbavancin-based prophylaxis

Start Date01 Mar 2025

Sponsor / Collaborator

St. Jude Children's Research Hospital, Inc.

NCT06798402

/ RecruitingPhase 2IIT

Effectiveness of Ciprofloxacin Intralesional Injection in the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate: a Parallel Groups Comparative Trial

The Aim of the trial to evaluate the effectiveness of intralesional ciprofloxacin 0.2% solution as a local injection in treating cutaneous leishmaniasis and compare its effect with intralesional sodium stibogluconate (SSG) 10% intravenous solution in cutaneous leishmaniasis as a local injection.
In a randomized parallel groups clinical trial, patients were divided into two groups based on therapeutic regimen: 1) intralesional sodium stibogluconate weekly injection and 2) intralesional ciprofloxacin injection. Each lesion was considered a case in the final analysis. Each lesion will be followed up for 90 days (censor endpoint) or until the lesions are cured.

Start Date07 Feb 2025

Sponsor / Collaborator

University of Al-Mustansiriyah

100 Clinical Results associated with Ciprofloxacin

100 Translational Medicine associated with Ciprofloxacin

100 Patents (Medical) associated with Ciprofloxacin

82,111

Literatures (Medical) associated with Ciprofloxacin

31 Dec 2025·Environmental Pollutants and Bioavailability

Comprehensive toxicity assessment of selected pharmaceuticals (ciprofloxacin, amoxicillin, and levofloxacin) on freshwater microalgae Scenedesmus obliquus : effect of media composition

Author: Poddar, Bikram ; Mandal, Sanmitra ; Bhattacharya, Bikramjit ; Rex M, Camil ; Chandrsekaran, Natarajan ; Mukherjee, Amitava

Antibiotics are widely used in health care to treat various infections.Excessive use and poor waste management make antibiotics a serious threat to aquatic ecosystems.Most of the ecotoxicol. assessments on freshwater microalgae are evaluated in the defined culture medium, which lacks environmental relevance.Hence, this study aimed to evaluate the toxicity of amoxicillin, ciprofloxacin, and levofloxacin on the freshwater microalga Scenedesmus obliquus in both lake water medium (LWM) and Blue green-11 medium (BG-11 M).Results indicated that levofloxacin exhibited the highest toxicity, followed by amoxicillin and ciprofloxacin in both LWM and BG-11 M.Pearson correlation and cluster heat map analyses revealed that oxidative stress generation was directly linked to reduced photosynthetic activity and cell viability.These findings suggest toxicity assessments conducted in defined culture media may modulate the toxicity levels compared to environmentally relevant media, like lake water.

31 Dec 2025·Plant Signaling & Behavior

Exploring the efficacy of drought tolerant, IAA-producing plant growth-promoting rhizobacteria for sustainable agriculture

Article

Author: Uzma, Malika ; Nisar, Atif ; Iqbal, Atia ; Gull, Tehseen ; Hasnain, Shahida ; Rahim, Muhammad Abdul ; Castro-Muñoz, Roberto ; Mahmoud, Mohamed H. ; Zongo, Eliasse

The growing human population and abiotic stresses pose significant threats to food security, with PGPR favorable as biofertilizers for plant growth and stress relief. In one study, soil samples from both cultivated and uncultivated plants in various cities were used to isolate rhizobacterial populations. Using 50 soil samples from both cultivated and uncultivated plants, isolated rhizobacterial populations were screened for various biochemical changes, PGP activities and morphological characteristics. A total of 199 rhizobacteria were isolated and screened for IAA production. The strain M28 produced maximum IAA 378.44 ± 2.5 µg ml^-1, M9 formed only 34.72 ± 0.15 µg ml^-1. About 19% of IAA producers were isolated from Multan, 18% Lahore, 15% from soils of Faisalabad and Sheikhupura, while 7% from Gujrat. The 21 isolates were drought tolerant to -0.14Mpa, 14 of those were PSB and 15 were N fixers. In PGP traits, maximum zinc solubility was expressed by M4 as 2 ± 0.5 cm of zone. The strain M22 produced amount of HCN, 40.12 ± 0.052 ppm. All isolates showed diverse behavior in biocompatibility, motility patterns and hydrophobicity. Selected drought tolerant strains were genetically identified by ribotyping. Multitrait PGPR could be effective biofertilizers rather than with single trait. The strain M28 having highest production of IAA, was gelatinase, methyl red positive and was also capable of nitrogen fixation. Moreover, it had maximum swimming (8.9 mm) and swarming (8.7 mm) activities after 24 h, indicating its best PGP traits for future use.

31 Dec 2025·VETERINARY QUARTERLY

Prevalence and characterization of ciprofloxacin-resistant Salmonella enterica spp. isolated from food animals during 2010–2023 in South Korea

Article

Author: Heo, Ye-Eun ; Ali, Md. Sekendar ; Lee, Yeon-Hee ; Kim, Min Young ; Lim, Suk-Kyung ; Choi, Ji-Hyun ; Kim, Ji-In ; Kim, Jae-Myung ; Hwang, Yu-Jeong ; Moon, Bo-Youn ; Kang, Hee-Seung

We isolated 6,561 Salmonella strains from food animals, cattle (n = 217), pigs (n = 1526), chickens (n = 3942), and ducks (n = 876). Isolates were evaluated for antimicrobial sensitivity, mutations in quinolone resistance determination regions (QRDRs), and plasmid-mediated quinolone resistance (PMQR) genes. Clonal relationship and genetic diversity were assessed by multi-locus sequence typing (MLST) and pulsed-field gel electrophoresis (PFGE). Overall, 3.1% of isolates exhibited resistance to ciprofloxacin. Commonly identified mutations in QRDRs were S83F, D87N, and D87G in gyrA; T57S and S80I in parC; and L416F in parE. Furthermore, mutations differed by serotypes. In S. Albany, S83F mutation in gyrA and T57S in parC were prevalent, while in S. Kentucky, S83F and D87N in gyrA, T57S and S80I in parC; and in S. Indiana, S83F and D87G in gyrA, T57S and S80R in parC, and L416F in parE were common. Amongst PMQRs, qnrS was mainly observed in S. Albany, aac(6')-Ib-cr in S. Indiana, and qnrB1 in S. Albany. Among STs, ST198 S. Kentucky was predominant, followed by ST292 S. Albany and ST17 S. Indiana. Of 26 pulsotypes, KX1KA1 was mainly identified in S. Kentucky, AX1AA1 in S. Albany, and IX1IA1 in S. Indiana. Taken together, ciprofloxacin-resistant Salmonella can pose health hazards to humans and other animals.

134

News (Medical) associated with Ciprofloxacin

07 Apr 2025

·www.prnewswire.com

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

Phase 2b study completed in amyotrophic lateral sclerosis (ALS) demonstrated lead asset PrimeC slows disease progression and functional decline Ongoing partnership discussions to advance PrimeC to Phase 3 study in ALS and commercialization Phase 3 study design for PrimeC in ALS aligned with FDA; planned initiation in 2025 CAMBRIDGE, Mass., April 7, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a clinical-stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today reports its financial results for the year ended December 31, 2024 and provides a business update. Business highlights from 2024 and to date PrimeC achieved primary and secondary clinical endpoints in PARADIGM Phase 2b study investigating PrimeC in ALS (n=68) with data showing the following: - PrimeC slowed disease progression (measured by ALSFRS-R) by approximately 33% after 18 months (p=0.007) - PrimeC reduced likelihood of mortality, hospitalization and respiratory support, resulting in an overall 58% improvement in survival rates. - PrimeC slowed functional decline, especially speaking and swallowing functions. - PrimeC demonstrated favorable safety and tolerability profile, achieving the study's primary endpoint. Phase 3 study design for PrimeC for ALS aligned with FDA following Type C meeting. Partnership discussions are continuing in order to advance PrimeC towards regulatory approval and eventual commercialization. Plans to file for early commercialization for PrimeC in Canada, with an estimated potential market opportunity of $100m-$150m in peak annual revenues. Key patent granted by U.S. Patent and Trademark Office (USPTO), extending the patent protection for the novel formulation of PrimeC until 2042. "2024 was a year of significant clinical progress for NeuroSense," stated NeuroSense CEO, Alon Ben-Noon. "We successfully completed our Phase 2b study for PrimeC in ALS, with data showing transformative results in a neurodegenerative indication of immense medical need. The results conclude with PrimeC's disease-modifying potential and strongly support advancing PrimeC towards a Phase 3 study. With positive FDA feedback on the proposed study design, we are putting everything in place for the next stage of NeuroSense's growth, driven by PrimeC's continued clinical development." Financial Results Research and development expenses for the years ended December 31, 2024 and 2023 were $5.7 million and $7.3 million, respectively. The decrease of $1.6, or 21.9%, was mainly attributed to a decrease in our expenses to subcontractors and consultants and a decrease in share-based payment expense. General and administrative expenses for the years ended December 31, 2024 and 2023 were $4.2 million and $4.8 million, respectively. The decrease of $0.6, or 12.5%, was mainly attributed to a decrease in share-based compensation and insurance costs and a decrease in salaries and social benefit expenses mainly due to decrease in the number of employees which were offset by an increase in professional services expenses. As of December 31, 2024, NeuroSense had cash of approximately $3.4 million. A summary of NeuroSense's consolidated financial results is included in the tables below. A copy of the Company's annual report on Form 20-F for the year ended December 31, 2024 has been filed with the U.S. Securities and Exchange Commission at and posted on the Company's investor relations website at . The Company will deliver a hard copy of its annual report, including its complete audited financial statements, free of charge, to its shareholders upon request at [email protected]. About ALS Amyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU. About PrimeC PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS that contribute to motor neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS. NeuroSense completed a Phase 2a clinical trial which met its safety and efficacy endpoints including reducing functional and respiratory deterioration and statistically significant changes in ALS-related biological markers indicating PrimeC's biological activity. PrimeC was granted Orphan Drug Designation by the U.S. Food and Drug Administration and the European Medicines Agency. About NeuroSense NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases. For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels. Forward-Looking Statements This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding ongoing partnership discussions, the timing of initiation of studies, regulatory filings, meetings and regulatory decisions, market potential and expected growth in the market. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the risk that the partnership discussions will not lead to execution of a definitive agreement, or that, if executed, will not lead to the current anticipated benefits to NeuroSense, a delay in the planned Phase 3 study for PrimeC in ALS, lower than anticipated market opportunity in Canada and elsewhere, that regulatory approvals for PrimeC will be delayed or not obtained in Canada or elsewhere; unexpected R&D costs or operating expenses, insufficient capital to complete development of PrimeC, a delay in the development of PrimeC, the timing of expected regulatory and business milestones, risks associated with meeting with the FDA and Health Canada to determine the best path forward following the results from PARADIGM clinical trial, including a delay in any such meeting; the potential for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the uncertainty regarding outcomes and the timing of current and future clinical trials; timing for reporting data; the development and commercial potential of any product candidates of Neurosense; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 7, 2025 and NeuroSense's subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law. Logo - SOURCE NeuroSense WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2Clinical ResultFinancial StatementOrphan Drug

04 Apr 2025

·www.prnewswire.com

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

Two presentations in the General Neurology and Late Breaker sessions will respectively cover new clinical and microRNA data from NeuroSense CAMBRIDGE, Mass., April 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics, Ltd. (NASDAQ: NRSN), a leading clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, today announced that two members of its Scientific Advisory Board will present new data from the Company's Phase 2b trial during the General Neurology and Late Breaker sessions at the 77th Annual American Academy of Neurology (AAN) Meeting. The presentations and conference will be taking place in San Diego, CA on April 8, 2025. Jeremy Shefner, M.D., Ph.D., Chair of the Department of Neurology and Senior Vice President at the Barrow Neurological Institute, will present new, compelling data from the Phase 2b trial of PrimeC, NeuroSense's novel investigational therapy for amyotrophic lateral sclerosis (ALS), at 2:24 p.m. His presentation, "Shifting the Paradigm: PrimeC, an Oral Candidate for ALS, Demonstrates Safety, Efficacy, and Target Engagement in an 18-Month Phase 2b Trial," will highlight PrimeC's disease-modifying potential in ALS treatment. "This exciting Phase 2b trial data underscores PrimeC's potential to redefine ALS treatment," says Shefner. "By demonstrating safety and tolerability, an indication of marked reduction in ALS progression, and multiple biomarker endpoints establishing PrimeC's biological activity, we move closer to offering a disease-modifying therapy that could lead to significantly improved clinical outcomes for people with ALS." Additionally, Jeffrey Rosenfeld, M.D., Ph.D., Professor of Neurology and Associate Chairman of Neurology at Loma Linda University School of Medicine, will present insights during a late breaker session at 6:15 p.m. on the role of microRNA modulation in ALS treatment, depicting the multi-targeted approach of PrimeC. His presentation, "MicroRNA Profiling and Iron-Related Modulation as Key Markers for Target Engagement in ALS Treatment with PrimeC," will shed new light on the understanding of PrimeC's mechanism of action in ALS. "PrimeC represents great potential to fundamentally change ALS treatment, with its multi-targeted approach revealing profound insights into disease mechanisms," says Rosenfeld. "By exploring microRNA modulation and iron-related pathways, we deepen our understanding of how PrimeC engages key targets of disease, offering new hope for tackling the complexities of ALS. These significant changes in such relevant biomarker endpoints reflecting target engagement, along with the clinical outcomes reported earlier, heighten our anticipation and enthusiasm for the forthcoming phase 3 trial of PrimeC ." About ALS Amyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU. About PrimeC PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS that contribute to motor neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS. NeuroSense completed a Phase 2a clinical trial which met its safety and efficacy endpoints including reducing functional and respiratory deterioration and statistically significant changes in ALS-related biological markers indicating PrimeC's biological activity. PrimeC was granted Orphan Drug Designation by the U.S. Food and Drug Administration and the European Medicines Agency. About NeuroSense NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases. For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels. Forward-Looking Statements This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the potential of PrimeC. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the risk of a delay in submission by the Company of its regulatory dossier, that regulatory approvals for PrimeC will be delayed or not obtained in Canada or elsewhere; unexpected R&D costs or operating expenses, insufficient capital to complete development of PrimeC, a delay in the reporting of additional results from PARADIGM clinical trial, the timing of expected regulatory and business milestones, risks associated with meeting with the FDA and Health Canada to determine the best path forward following the results from PARADIGM clinical trial, including a delay in any such meeting; the potential for PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the uncertainty regarding outcomes and the timing of current and future clinical trials; timing for reporting data; the development and commercial potential of any product candidates of Neurosense; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 4, 2024 and NeuroSense's subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law. Logo: SOURCE NeuroSense WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2Orphan DrugClinical Result

15 Jan 2025

·www.prnewswire.com

Visby Medical Secures Additional $3.9M from CARB-X to Fight Antibiotic Resistance with PCR-Based Mutation Detection at the POC

SAN JOSE, Calif., Jan. 15, 2025 /PRNewswire/ -- Visby Medical™, a leading innovator in rapid PCR diagnostics, has secured an additional $3.9 million from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator ( CARB-X) to accelerate its fight against antibiotic resistance. This funding builds on a $1.2 million grant awarded in December 2023 and propels Visby's development of groundbreaking diagnostic tools that pinpoint resistance-conferring mutations in infections, starting with ciprofloxacin susceptibility. Continue Reading The additional funding will advance Visby's pioneering work funded by CARB-X, which has demonstrated its preliminary ability to detect Neisseria gonorrhoeae (NG) from urine and vaginal swabs and distinguish ciprofloxacin-susceptible strains. Next, Visby will continue development toward integrating these capabilities into its Visby Medical Sexual Health Test, which detects chlamydia, gonorrhea, and trichomoniasis. The company is also developing a digital companion app and AI-driven tools to make result interpretation seamless, while working on cost-cutting innovations for its platform. Latest CARB-X grant propels Visby development of diagnostics to pinpoint resistant mutations in STIs. Post this Ciprofloxacin is a former frontline antibiotic that has been sidelined due to widespread resistance. With Visby's rapid test, doctors could determine if this convenient, inexpensive oral antibiotic is effective and reserve ceftriaxone—currently the only antibiotic that remains effective against resistant gonorrhea—for truly resistant cases. "Antibiotic resistance is a critical concern across all of healthcare, and especially in sexually transmitted infections for which numbers continue to rise," explained Gary Schoolnik, MD, Chief Medical Officer of Visby Medical. "Particularly for N. gonorrhoeae, which is a poster child for acquiring resistance, unlocking the treatment potential of ciprofloxacin could mean the difference between extending the lifetime of ceftriaxone either for decades, or only a handful of years." About Visby Medical Founded in 2012, Visby Medical is transforming the order of diagnosis and treatment for infectious diseases so clinicians can test, talk with, and treat the patient in a single visit. The Company developed a proprietary technology platform that is the world's first instrument-free, single-use PCR platform that fits in the palm of your hand and rapidly tests for serious infections. Their commercialized point-of-care tests for sexually transmitted infections (STIs) and respiratory infections (COVID-19 and the flu) deliver true PCR results in under 30 minutes. For more information, visit . Follow Visby Medical on LinkedIn. CARB-X funding for this research is supported by federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number 75A50122C00028, and by awards from Wellcome (WT224842), Germany's Federal Ministry of Education and Research (BMBF), and the UK Department of Health and Social Care as part of the Global Antimicrobial Resistance Innovation Fund (GAMRIF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views CARB-X or its funders. Media Contact: [email protected] SOURCE Visby Medical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 Deals associated with Ciprofloxacin

External Link

KEGG	Wiki	ATC	Drug Bank
D00186	Ciprofloxacin	S01AE03 J01MA02 S03AA07	DB00537

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Otitis Externa	United States	ALK-Abello A/S	10 Dec 2015
Otitis Media With Effusion	United States	ALK-Abello A/S	10 Dec 2015
Hospital-acquired pneumonia	United States	Bayer HealthCare Pharmaceuticals, Inc.	02 Feb 2015
Non-complicated skin and skin structure infection	United States	Bayer HealthCare Pharmaceuticals, Inc.	02 Feb 2015
Plague	United States	Bayer HealthCare Pharmaceuticals, Inc.	02 Feb 2015
Bronchiectasis	China	Bayer Pharma AG	22 Sep 2013
Bacterial prostatitis	Australia	Ipca Pharma (Australia) Pty Ltd.	05 Nov 2004
Bronchial Diseases	Australia	Ipca Pharma (Australia) Pty Ltd.	05 Nov 2004
Gastroenteritis	Australia	Ipca Pharma (Australia) Pty Ltd.	05 Nov 2004
Gonococcal urethritis	Australia	Ipca Pharma (Australia) Pty Ltd.	05 Nov 2004
Uterine Cervicitis	Australia	Ipca Pharma (Australia) Pty Ltd.	05 Nov 2004
Pyelonephritis	United States	Bayer HealthCare Pharmaceuticals, Inc.	25 Mar 2004
Anthrax	Japan	Bayer Yakuhin Ltd.	21 Dec 2001
Cholangitis	Japan	Bayer Yakuhin Ltd.	22 Sep 2000
Cholecystitis	Japan	Bayer Yakuhin Ltd.	22 Sep 2000
Peritonitis	Japan	Bayer Yakuhin Ltd.	22 Sep 2000
Pneumonia	Japan	Bayer Yakuhin Ltd.	22 Sep 2000
Complicated urinary tract infection	United States	Bayer HealthCare Pharmaceuticals, Inc.	26 Sep 1997
Acute sinusitis	United States	Bayer Pharmaceuticals Corp.	26 Dec 1990
Acute sinusitis	United States	Bayer HealthCare Pharmaceuticals, Inc.	26 Dec 1990

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute otitis externa	Phase 3	United States	Otonomy, Inc.	01 Jun 2016
Acute otitis externa	Phase 3	Canada	Otonomy, Inc.	01 Jun 2016
Infective otitis externa	Phase 3	United States	Otonomy, Inc.	01 Jun 2016
Infective otitis externa	Phase 3	Canada	Otonomy, Inc.	01 Jun 2016
Otitis Media	Phase 3	United States	Otonomy, Inc.	01 Oct 2015
Non-cystic fibrosis bronchiectasis	Phase 3	United States	Novartis AG	02 May 2013
Non-cystic fibrosis bronchiectasis	Phase 3	United States	Bayer AG	02 May 2013
Non-cystic fibrosis bronchiectasis	Phase 3	Japan	Bayer AG	02 May 2013
Non-cystic fibrosis bronchiectasis	Phase 3	Japan	Novartis AG	02 May 2013
Non-cystic fibrosis bronchiectasis	Phase 3	Argentina	Bayer AG	02 May 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03850379 (Pubmed \| Int J Infect Dis)	Phase 2	Hematopoietic stem cell transplantation	308	Ciprofloxacin	hgewsyncvf(ajamlwropz) = jhhueabdid arrtefdfgf (ayoklskiyw ) View more	Positive	15 Jul 2024
				Levofloxacin	hgewsyncvf(ajamlwropz) = pcafkointr arrtefdfgf (ayoklskiyw ) View more
NCT02773732 (phase 1b, Pubmed)	Phase 1	Refractory acute myeloid leukemia	11	Ciprofloxacin 750 mg	ogtzfigvwb(logeizzwqa) = juujuhnpln eocifvmjjd (hmhzenbpll ) View more	Negative	06 Jun 2024
				Ciprofloxacin 1000 mg	ogtzfigvwb(logeizzwqa) = kanveyccxh eocifvmjjd (hmhzenbpll ) View more
NCT03969758 (clinicaltrials.gov PRS ID: NCT03969758, 31/05/2019, Pubmed)	Phase 3	Liver Abscess	140	Ciprofloxacin	xqznrneepu(gmofccsivd) = hrqyzeymdb bhxypnhmuz (vdweagnvzo ) View more	Positive	20 May 2024
				Cefixime	xqznrneepu(gmofccsivd) = effwpuozyi bhxypnhmuz (vdweagnvzo ) View more
AAN2024	Not Applicable	Myasthenia Gravis	-	Ciprofloxacin	kcafopgotv(aqmkbcbdmj) = cfzoavcvsl noeplrdyko (ctriqcybhi )	-	09 Apr 2024
				Levofloxacin	kcafopgotv(aqmkbcbdmj) = ojwnhnsuzk noeplrdyko (ctriqcybhi )
Tandem Meetings ASTCT and CIBMTR2024	Not Applicable	Hematopoietic stem cell transplantation	400	Ciprofloxacin (Allogeneic haematopoietic cell transplantation (allo-HCT))	pshvfdnnjo(bcqrnxurpr) = ylatfwpdfe bxmfdgxdfz (spbketqhhn ) View more	Positive	01 Feb 2024
NCT03850379 (not available, Tandem Meetings ASTCT and CIBMTR2023)	Phase 2	Hematopoietic stem cell transplantation	-	Ciprofloxacin	xmlnlnqjdd(legepjtplg) = gxsdmquocb uayikucsou (folcdggxmi ) View more	Positive	01 Feb 2023
				Levofloxacin	xmlnlnqjdd(legepjtplg) = aizifbpqrm uayikucsou (folcdggxmi ) View more
NCT01265173 (Pubmed \| Am J Gastroenterol)	Not Applicable	Spontaneous bacterial peritonitis First line	261	Cefotaxime	cvozsanfnl(wwajuqlhmm) = idsbqkykuj fomepttfuh (xcefnujnui )	-	02 Jan 2023
				Ceftriaxone	cvozsanfnl(wwajuqlhmm) = cmihteejia fomepttfuh (xcefnujnui )
NCT05436678 (Biospace) Manual	Phase 1	Amyotrophic Lateral Sclerosis	20	Celecoxib+Ciprofloxacin+Ciprofloxacin+Celecoxib	iuskzukzjl(dtsgurbevt) = as a comparison of PrimeC to ciprofloxacin and celecoxib shows that the AUC0-t, and AUC0-∞ are lower for both components of PrimeC compared to the highest approved doses of each of the components administered separately. yyuxypzysx (wrowinkbpa ) View more	Positive	28 Sep 2022
NCT02773732 (UF-AML-CE-101 \| phase 1b, CTgov)	Phase 1/2	Refractory acute myeloid leukemia	11	Etoposide+Ciprofloxacin 1000 MG (Ciprofloxacin Dose Level +1)	kttmvypdlf = cvjzqfhifn amwxppouuf (tznllfkcza, illjhkzhfj - zwokdwaryd) View more	-	05 Aug 2022
				Etoposide+Ciprofloxacin 750 MG (Ciprofloxacin Dose Level 0)	kzdkpklvzc(cutqlwwzun) = lpjukvinyr jvgzbxucio (nqwspchihl, yhtcyplosz - pfenrcuzsj) View more
P319 (EBMT2022)	Not Applicable	Hematopoietic stem cell transplantation	38	Ciprofloxacin	qfasemgqzv(ffbcxewijt) = yuubhteijz dlwjarkgoc (rfkjqtxvms ) View more	Positive	19 Mar 2022
				Rifaximin	qfasemgqzv(ffbcxewijt) = vwgkbxwdyl dlwjarkgoc (rfkjqtxvms ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis